Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Tech-Led global selloff, Fed rate fears weigh on Indian equities
Indian stock markets experienced their sharpest single-day drop in nearly a month, mirroring a global tech sell-off. The Nifty 50 and BSE Sensex both fell significantly, influenced by a strong US dollar and profit-taking after recent gains. While pharma and healthcare sectors showed resilience, most others, including metals and IT, declined. Market volatility increased, with analysts watching key support levels closely.
Sensex rises 291 points, Nifty tops 24,100 on cooling crude and FII support
Domestic equities advanced on Monday as cooling oil prices and fresh FII inflows fuelled risk appetite. Buying in heavyweight Reliance Industries and healthcare counters propelled the Nifty past the 24,100 level. The gains were partly offset by weakness in consumer durables and FMCG stocks.
Market snaps five-day rally as IT rout drags Nifty below 24,050
The domestic equity benchmarks ended sharply lower on Friday, snapping a five-session winning streak. The Nifty slipped below the 24,050 mark as a steep sell-off in IT stocks weighed on sentiment. Technology shares came under pressure after Accenture trimmed its revenue growth guidance and flagged weak demand visibility, raising concerns about global IT spending. Healthcare and pharma stocks, however, bucked the broader weakness. Investor sentiment was further affected by continued FII selling, weak global cues and rising geopolitical tensions in the Middle East. Profit booking following the recent market rally also added to the downside pressure.
HealthQuad looking at deeper opportunities in new age healthcare with its Fund III
The early growth investor sees a wider and deeper opportunity across new age healthcare models, as demand and the pipeline of entrepreneurs building stronger, lasting businesses continues to grow
Nifty extends winning streak to fifth day; banks, healthcare stocks lead gains
The S&P BSE Sensex advanced 254.36 points or 0.33% to 77,409.98. The Nifty 50 index rose 82.30 points or 0.34% to 24,168. In five sessions, the Sensex jumped 4.85% and Nifty climbed 4.35%.
HDFC MF, ADIA among buyers as Sepia Investments offloads Rs 749 crore in Corona Remedies via block deal
Sepia Investments and Anchor Partners sold shares worth about Rs 777 crore in Corona Remedies through block deals. HDFC Mutual Fund emerged as the largest buyer, while several institutional investors, including Aberdeen entities, ADIA, Invesco and WhiteOak, also accumulated stakes.
Nifty tops 23,850 as oil slump sparks broad-based rally
The key equity benchmark indices extended gains for a second consecutive session on Monday, supported by a sharp decline in crude oil prices and optimism surrounding a US-Iran peace agreement. Buying was broad-based, with most sectoral indices ending in the green. Investor sentiment was further buoyed by strong global cues, a stronger rupee and easing market volatility. The Nifty settled above the 23,850 mark, led by gains in consumer durables and auto stocks. However, pharma and healthcare shares bucked the trend and closed lower.
Nifty 50 target cut by Citi to 26,000 - Key risk factors, top picks explained
Citi has highlighted Financials, Telecom, Healthcare, Defence and Utilities as their key "overweights", while IT Services, Staples, Metals are their top "underweights." It has also added Hitachi Energy into its list of top picks having initiated coverage on the stock recently.
Further consolidation ahead for Nifty? Here's today's outlook and top picks
Ajit Mishra of Religare Broking has recommended buying the shares of Fortis Healthcare, RBL Bank, and Eternal today
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.